Biogen Inc.: Biogen Announces FDA's 3-Month Extension of Review Period for the New Drug Application for Tofersen

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Priya Singhal ,Mike Hencke ,Edan Haro ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Kenneth Murray ,Linkedin ,Twitter ,Ionis Pharmaceuticals Inc ,Regulatory Sciences ,Drug Administration ,Nasdaq ,Exchange Commission ,Youtube ,Facebook ,Prescription Drug User Fee Act ,Major Amendment ,Global Safety ,Interim Head ,Ionis Pharmaceuticals ,Amyotrophic Lateral Sclerosis ,Continuous Commitment ,Sir Kenneth Murray ,Nobel Prize ,Healthy Lives ,Private Securities Litigation Reform Act ,Neurol Neurosurg ,Biogen ,Nnounces ,Month ,Extension ,Review ,Eriod ,Drug ,Application ,Ofersen ,